Thomas Powles, MD, on Urothelial Carcinoma: Results From the IMvigor211 Trial
2018 Genitourinary Cancers SymposiumThomas Powles, MD, of Barts Cancer Institute, discusses phase III study findings on atezolizumab vs chemotherapy in platinum-treated locally advanced or metastatic urothelial carcinoma, with an emphasis on immune biomarkers, tumor mutational burden, and clinical outcomes (Abstract 409).
Related Videos
John J. Coen, MD, on Bladder Cancer: Results From the NRG/RTOG 0712 Trial
John J. Coen, MD, of 21st Century Oncology, discusses phase II study findings on selective bladder preservation with twice-daily radiation plus fluorouracil/cisplatin or daily radi...
Daniel J. George, MD, on RCC: Results From the Alliance A031203 CABOSUN Trial
Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma ...
Eric J. Small, MD, on Prostate Cancer: Results From the SPARTAN Trial
Eric J. Small, MD, of the University of California, San Francisco, discusses phase III findings on apalutamide vs placebo in patients with nonmetastatic castration-resistant prosta...
Robert G. Bristow, MD, PhD, on Prostate Cancer: Keynote Lecture
Robert G. Bristow, MD, PhD, of Manchester Cancer Research Centre, discusses germline and somatic mutations; new ways to generate biomarkers that may describe tumor complexity; and ...
Laurence Albiges, MD, PhD, on RCC: Results From the NIVOREN GETUG-AFU 26 Trial
Laurence Albiges, MD, PhD, of the Gustave Roussy Cancer Centre, discusses study findings on the safety and efficacy of nivolumab in metastatic renal cell carcinoma (Abstract 577).<...
